Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorapaxar in Secondary Prevention of Atherothrombotic Ischemic Events
NCT00526474Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2007
- Primary completion
- Dec 2011
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of vorapaxar in atherosclerosis, sponsored by Merck & Co.. Started Sep 2007; status: completed.
02
Drugs
vorapaxar
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT00526474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00526474.